Evidence map›Paper›PMID 40877508›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Production of mRNA-Loaded Dendritic Cell Cancer Vaccines.

Turid Kirsti Hønnåshagen, Lisbeth Johanne Skoge, Stein Sæbøe-Larssen, Hege Håkenstad, Gunnar Kvalheim, Mouldy Sioud

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Turid Kirsti HønnåshagenSection for Cellular Therapy, Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Lisbeth Johanne SkogeSection for Cellular Therapy, Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Stein Sæbøe-LarssenSection for Cellular Therapy, Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Hege HåkenstadSection for Cellular Therapy, Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Gunnar KvalheimSection for Cellular Therapy, Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Mouldy SioudDivision of Cancer Medicine, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. mosioud@medisin.uio.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) and play a crucial role in antitumor immunity. Consequently, various strategies have been explored to utilize DCs as therapeutic vaccines, leveraging their ability to target tumor cells. A variety of antigen formulations were tested to evaluate their efficacy in vaccination, including purified tumor-associated antigens, synthetic polypeptides, and mRNA encoding tumor-associated antigens or neoantigens. In this protocol, we describe the ex vivo generation of dendritic cells from peripheral blood mononuclear cells and loading with in vitro transcribed mRNA for vaccination purposes under Good and Manufacturing Practices.

Indexed as

Cancer VaccinesDendritic CellsNeoplasmsRNA, MessengerAntigens, NeoplasmHumansLeukocytes, MononuclearAntigens, NeoplasmCancer VaccinesRNA, MessengerCancer vaccinesDendritic cellsElectroporationMonocytesmRNA

Identifiers

PMID40877508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.